MINNEAPOLIS, Aug. 13, 2014 /PRNewswire/ -- Danish medical
device company Coloplast delivered revenue of USD* 1,654 million
(DKK 9,214 million) and 9% organic
growth in the first nine months of the 2013/14 financial year. Q3
organic growth was 8%.
EBIT before special items was up by 13% to USD 547 million (DKK 3,047
million). The EBIT margin before special items was 33%
against 31% in 9M 2012/13.
Delivering on ambitious targets
"I'm pleased with the
solid financial results we are announcing today. We are continuing
our string of healthy growth in all business areas and in all
regions, and our consolidated profit is matching the high
expectations we have for our company," said Coloplast CEO
Lars Rasmussen.
Global sales growth by business area was as follows: Ostomy Care
8%, Continence Care 11%, Urology Care 10% and Wound & Skin Care
10%. Coloplast grew its European business by 6%, Other Developed
Markets by 10% and Emerging Markets by 24%.
Consumer centered strategy
Senior Vice President,
Chronic Care US, Ed Veome says: "The
US is an important market for Coloplast and we have invested to
grow our business as we see great potential. It is very encouraging
that we have seen strong sales performance in our continence and
ostomy care product lines."
"We're pursuing a strategy that puts the consumer in the center.
The majority of our users in the US have overcome critical
conditions that led them to our products, and we want to help them
return to their normal lives. We can only do that by listening and
responding to their needs."
Coloplast employs more than 500 people in the US and has it US
headquarter in Minneapolis,
Minnesota. Globally Coloplast employs more than 9.000 with
its products being sold in more than 100 countries around the
world. Coloplast is listed on the Copenhagen Stock Exchange, part
of the NASDAQ OMX Group and has a market cap of around USD 18 billion (DKK 100
billion).
Financial guidance for 2013/14 unchanged
Following the
Q3 interim report, Coloplast continues to expect full-year organic
revenue growth of about 9% and of about 7% in DKK. The company
continues to expect the EBIT margin before special items to be
33-34% at constant exchange rates and about 33% in DKK.
For further information, click here to read the Q3 Interim
Report.
*At exchange rate USD/DKK 5,57
www.coloplast.com
|
|
Financial
highlights and key ratios
|
|
|
|
|
|
|
Financial
highlights
and key ratios
DKKm
|
9M
2013/14
|
9M
2012/13
|
Change
|
FY
2012/13
|
|
Revenue
|
9,214
|
8,665
|
6%
|
11,635
|
|
EBIT
|
2,047
|
2,699
|
(24%)
|
3,672
|
|
EBIT
margin
|
22%
|
31%
|
(9) p.p.
|
32%
|
|
Special
items
|
1,000
|
-
|
-
|
-
|
|
|
|
|
|
|
EBIT before special
items
|
3,047
|
2,699
|
13%
|
3,672
|
|
EBIT margin before
special items
|
33 %
|
31%
|
2 p.p.
|
32%
|
|
Sales performance
by
business area
|
9M
2013/14
DKKm
|
9M
2012/13
DKKm
|
Organic
growth
|
Reported
growth
|
|
Ostomy Care
|
3,764
|
3,613
|
8%
|
4%
|
|
Continence
Care
|
3,288
|
3,029
|
11%
|
9%
|
|
Urology Care
|
898
|
844
|
10%
|
6%
|
|
Wound & Skin
Care
|
1,264
|
1,179
|
10%
|
7%
|
|
Revenue
|
9,214
|
8,665
|
9%
|
6%
|
Coloplast develops products and services that make life easier
for people with very personal and private medical conditions.
Working closely with the people who use our products, we create
solutions that are sensitive to their special needs. We call this
intimate healthcare. Our business includes ostomy care, urology and
continence care and wound and skin care. We operate globally and
employ more than 9,000 people.
SOURCE Coloplast